article thumbnail

UK university partnership wins £1.8m for drug discovery research

Drug Discovery World

million grant to engineer microbial cell factories to produce membrane proteins which will support future drug screening and sustainable chemical production. Membrane proteins are crucial molecules on the surface of cells with numerous biological functions, such as sensing hormones or cell communication.

Research 105
article thumbnail

UK NICE grants approval for breast cancer drug combination

Pharmaceutical Technology

The 'life-extending' drug combination is recommended for usage in adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer who have previously received hormone therapy. It acts by hindering proteins in cancer cells to avert cell division and growth.

HR 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New podcast: A new paradigm of appetite and hunger

Drug Discovery World

In this episode, Megan Thomas is in conversation with Tien Lee, CEO of Aardvark Therapeutics, a San Diego-based biotech company in Phase II studies of its drug, ARD-101, a type 2 bitter taste receptor (TAS2R) which is taken orally and remains in the human gut unlike GLP-1 which is systemic.

article thumbnail

A new paradigm of appetite and hunger

Drug Discovery World

In this episode, Megan Thomas is in conversation with Tien Lee, CEO of Aardvark Therapeutics, a San Diego-based biotech company in Phase II studies of its drug, ARD-101, a type 2 bitter taste receptor (TAS2R) which is taken orally and remains in the human gut unlike GLP-1 which is systemic.

article thumbnail

FDA accepts AstraZeneca’s NDA for breast cancer combination therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has accepted AstraZeneca’s new drug application (NDA) for the combination of capivasertib and FASLODEX (fulvestrant), and granted it priority review. The regulator will announce its decision during the fourth quarter of 2023.

HR 245
article thumbnail

UK NICE recommends Novartis’ combination therapy for breast cancer

Pharmaceutical Technology

The UK National Institute for Health and Care Excellence (NICE) has recommended Novartis Pharmaceuticals UK’s Piqray (alpelisib) along with hormonal therapy fulvestrant to treat hormone receptor+, HER2-, PIK3CA-mutated locally advanced or metastatic breast cancer.

Hormones 147
article thumbnail

Lumos Pharma’s Patient-Centric Strategy for Rare Disease Drug Development

XTalks

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This venture also led me to identify a gap in the market for contract manufacturing of recombinant proteins.